Multiple myeloma cells’ capacity to decompose H2O2 determines lenalidomide sensitivity

Sinto Sebastian(Mayo Clinic in Arizona), Rafaël Fonseca(Mayo Clinic in Arizona)
Blood
December 28, 2016
10.1182/blood-2016-09-738872
Cited by 46

Related Papers

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
|Leukemia|2009|877
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
|The Lancet Oncology|2021|266
Ductal Carcinoma in Situ of the Breast
|Annals of Internal Medicine|1997|245
Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study
|Blood|2021|161
OAB-052: Impact of chromosome 1 abnormalities on newly diagnosed multiple myeloma treated with proteasome inhibitor, immunomodulatory drug, and dexamethasone: analysis from the ENDURANCE ECOG-ACRIN E1A11 trial
|Clinical Lymphoma Myeloma & Leukemia|2021|16